← All trials
NCT03749187
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 3, 2019
- Primary completion
- Jun 30, 2022
- Completion date
- Jul 31, 2027
- First posted
- —
- Last posted
- —
- Enrollment
- 78
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- BeOne MedicinesCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoReponsible party - principal investigator
- The Pacific Pediatric Neuro-Oncology ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.